What exactly did Jefferies change for CytomX on March 18, 2026?

Jefferies maintained a **Buy** rating for CTMX and raised the price target to **$16** on March 18, 2026. The firm called the stock a buying opportunity, signaling conviction in CytomX’s pipeline despite near-term dilution from an equity offering.

How should investors interpret the CTMX analyst rating now?

The CTMX analyst rating from Jefferies is bullish but conditional. It supports upside tied to clinical progress, while investors should weigh financing dilution, trial risk, and their time horizon before acting.

Does the Jefferies note affect CytomX’s share price immediately?

Analyst notes can influence sentiment and trading, but immediate price moves also reflect news like the **$250 million** offering. CTMX showed a reported **-8.65% ($-0.42)** change around the update, showing mixed market reaction.

What does Meyka AI’s B+ grade mean for CTMX investors?

Meyka AI rates CTMX **B+** based on benchmark and sector comparison, financial growth, key metrics, and analyst consensus. The grade flags upside potential and dilution risk and is not investment advice.

Analyst Ratings

Jefferies Maintains Buy on CTMX (CytomX Therapeutics) March 18, 2026

ByDanny Kontos March 19, 2026March 19, 2026

Jefferies maintained a Buy on CTMX (CytomX Therapeutics, Inc.) on March 18, 2026, raising its price target to $16. The firm called the stock a “buying opportunity” and left its Buy rating intact. This CTMX analyst rating update arrives as the company completes a $250 million offering and outlines registrational plans for Varseta-M. Investors should weigh Jefferies’ confidence against the recent -8.65% ($-0.42) intraday move and the company’s near-term financing activity.